Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424408 | 0.83 | ALDH1A1 (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL25933055 | 0.81 | MEN1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL2603237 | 0.80 | MEN1 (0.47) | MEN1KMT2AALDH1A1DPP4DPP8 | |
| SCHEMBL12385976 | 0.79 | CYP2D6 (0.53) | MEN1KMT2AALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL14147221 | 0.79 | MEN1 (0.46) | MEN1KMT2AALDH1A1DPP4DPP8 | |
| SCHEMBL14147672 | 0.79 | MEN1 (0.46) | MEN1KMT2AALDH1A1DPP4DPP8 | |
| SCHEMBL12125453 | 0.79 | KMT2A (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13403905 | 0.79 | MEN1 (0.46) | MEN1KMT2AALDH1A1DPP4DPP8 | |
| SCHEMBL8261295 | 0.78 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1SMN1; SMN2DPP4 | |
| SCHEMBL25068495 | 0.77 | SMYD3 (0.49) | MEN1KMT2AALDH1A1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | MEN1 298/4885KMT2A 1997/4885ALDH1A1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.